

Cover Story
By Matthew Bin Han Ong
For more than four decades, Steven Rosenberg's work on tumor infiltrating lymphocytes has met with equal measures of skepticism and cheer—but now, as more patients across multiple cancer types respond to cell transfer immunotherapy, researchers are eager to join the movement Rosenberg indisputably leads.
By Jordan Williams
In Brief
Clinical Roundup
Drugs & Targets
Trending Stories
- Trump administration seeks to slash NIH by roughly 40% as 27 institutes and centers are whittled down to eight
NCI to remain intact, but its finances are uncertain; FDA is spared big cuts - John Burklow replaced by Seana Cranston as NIH chief of staff
- In the Headlines: What’s in Trump’s draft budget?
- NCI summarizes changes to the CCSG NOFO
- DOD cancer research programs face 57% funding cut in year-long continuing resolution
Pancreatic, lung, kidney cancer research programs eliminated - AACR announces 2025 Scientific Achievement Award recipients